Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Operating Income: 2012-2024

Historic Operating Income for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to -$111.7 million.

  • Coherus Oncology's Operating Income rose 5.38% to -$44.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.7 million, marking a year-over-year increase of 58.48%. This contributed to the annual value of -$111.7 million for FY2024, which is 45.05% up from last year.
  • Per Coherus Oncology's latest filing, its Operating Income stood at -$111.7 million for FY2024, which was up 45.05% from -$203.2 million recorded in FY2023.
  • Over the past 5 years, Coherus Oncology's Operating Income peaked at $156.3 million during FY2020, and registered a low of -$263.9 million during FY2021.
  • Its 3-year average for Operating Income is -$190.6 million, with a median of -$203.2 million in 2023.
  • As far as peak fluctuations go, Coherus Oncology's Operating Income soared by 45.05% in 2020, and later plummeted by 268.79% in 2021.
  • Over the past 5 years, Coherus Oncology's Operating Income (Yearly) stood at $156.3 million in 2020, then tumbled by 268.79% to -$263.9 million in 2021, then grew by 2.64% to -$256.9 million in 2022, then increased by 20.90% to -$203.2 million in 2023, then soared by 45.05% to -$111.7 million in 2024.